Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQC2731 injection in moderate to very severe COPD
CTR20244467Phase 2Active
- Sponsor
- China Grand Pharmaceutical and Healthcare Holdings
- Start
- Dec 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing TQC2731 with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Dec 2024; status: active.
02
Drugs
bosakitug
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20244467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244467.